1 / 4

AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c

AMYLIN PHARMACEUTICALS (AMLN) www.amylin.com Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market cap: 2.04 Bil Revenue: $13 Mil Expenses: ($119) Mil Net Loss: ($109) Mil P/E: N/A EPS: -1.51 Estimated target price: 27.3

albert
Download Presentation

AMYLIN PHARMACEUTICALS (AMLN) amylin Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market c

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AMYLIN PHARMACEUTICALS (AMLN)www.amylin.com Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market cap: 2.04 Bil Revenue: $13 Mil Expenses: ($119) Mil Net Loss: ($109) Mil P/E: N/A EPS: -1.51 Estimated target price: 27.3 Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. Estimated 177 Mil people worldwide suffer from diabetes, 18 Mil of which have type I diabetes (juvenile, autoimmune), and 159 Mil have type 2 (adult). Approx. 11.5 Mil in U.S. have diabetes, with 1 Mil new cases each year. 10-Q 8K pos. results invest for Exenatide@ 25 SEC Exenatide PIII results reported

  2. Amylin announces SEC investigation of conf. call violation of Regulation FD GS conf. Call: Amylin CEO discusses FDA rejection of Symlin Club Biomed buys 200 shrs AMLN @ ~ 25 Amylin announces positive P-III results for Exenatide

  3. January 2003-2004 AMLN v AMEX BIOTECH INDEX AMLN v NASDAQ BIOTECH INDEX

  4. PATENTS Hold 36 U.S. Patents and 33 pending U.S. patent applications: 17 issued to development and commercialization of SYMLIN (10 pending) 1 issued to development and commercialization of EXENATIDE (15 pending) Includes SYMLIN and amylin analogs or agonists, methods of synthesis for these molecules, methods of preparing these products, BUT DO NOT have composition-of-matter patent for EXENATIDE or EXENATIDE LAR.

More Related